/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ziv-aflibercept for DME provides BCVA gains, lower dosing burden

    Results of a 1-year randomized controlled trial investigating treatment for diabetic macular edema (DME) show that intravitreal ziv-aflibercept (Zaltrap, Sanofi Genzyme) 1.25 or 2.5 mg is safe, according to Masoud Soheilian, MD.

    In addition, when compared with intravitreal bevacizumab (Avastin, Genentech), it provides significantly greater improvement in best-corrected visual acuity (BCVA) with a lower dosing burden, said Dr. Soheilian, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

    The double-blind study also found that the functional benefit of ziv-aflibercept over bevacizumab was particularly seen in eyes with BCVA ≤20/50.

    Anatomical data showed that ziv-aflibercept 2.5 mg was associated with significantly greater reduction in central macular thickness (CMT) compared with both the lower dose of ziv-aflibercept and bevacizumab.

    “DRCR.net Protocol T demonstrated that intravitreal aflibercept (Eylea, Regeneron) was more effective than bevacizumab and ranibizumab (Lucentis, Genentech) for improving vision in DME patients with baseline BCVA ≤ 20/50,” Dr. Soheilian said.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results